Please use this identifier to cite or link to this item: https://doi.org/10.1186/s12933-016-0387-4
DC FieldValue
dc.titleThe clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: The Rotterdam study
dc.contributor.authorHerpt, T.T.W
dc.contributor.authorDehghan, A
dc.contributor.authorHoek, M
dc.contributor.authorIkram, M.A
dc.contributor.authorHofman, A
dc.contributor.authorSijbrands, E.J.G
dc.contributor.authorFranco, O.H
dc.date.accessioned2020-10-27T10:43:49Z
dc.date.available2020-10-27T10:43:49Z
dc.date.issued2016
dc.identifier.citationHerpt, T.T.W, Dehghan, A, Hoek, M, Ikram, M.A, Hofman, A, Sijbrands, E.J.G, Franco, O.H (2016). The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: The Rotterdam study. Cardiovascular Diabetology 15 (1) : 69. ScholarBank@NUS Repository. https://doi.org/10.1186/s12933-016-0387-4
dc.identifier.issn14752840
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/181373
dc.description.abstractBackground: To evaluate the clinical value of metabolic syndrome based on different definitions [American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), International Diabetes Federation (IDF) and European Group for the Study of Insulin Resistance (EGIR)] in middle-aged and elderly populations. Methods: We studied 8643 participants from the Rotterdam study (1990-2012; mean age 62.7; 57.6% female), a large prospective population-based study with predominantly elderly participants. We performed cox-proportional hazards models for different definitions, triads within definitions and each separate component for the risk of incident type 2 diabetes mellitus, coronary heart disease, stroke, cardiovascular- and all-cause mortality. Results: In our population of 8643 subjects, metabolic syndrome was highly prevalent (prevalence between 19.4 and 42.4%). Metabolic syndrome in general was associated with incident type 2 diabetes mellitus (median follow-up of 6.8years, hazard ratios 3.13-3.78). The associations with coronary heart disease (median follow-up of 7.2years, hazard ratios 1.08-1.32), stroke (median follow-up of 7.7years, hazard ratios 0.98-1.32), cardiovascular mortality (median follow-up of 8.2years, ratios 0.95-1.29) and all-cause mortality (median follow-up of 8.7years, hazard ratios 1.05-1.10) were weaker. AHA/NHLBI- and IDF-definitions showed similar associations with clinical endpoints compared to the EGIR, which was only significantly associated with incident type 2 diabetes mellitus. All significant associations disappeared after correcting metabolic syndrome for its individual components. Conclusions: Large variability exists between and within definitions of the metabolic syndrome with respect to risk of clinical events and mortality. In a relatively old population the metabolic syndrome did not show an additional predictive value on top of its individual components. So, besides as a manner of easy identification of high risk patients, the metabolic syndrome does not seem to add any predictive value for clinical practice. © 2016 van Herpt et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectglucose
dc.subjecthigh density lipoprotein cholesterol
dc.subjecttriacylglycerol
dc.subjectadult
dc.subjectArticle
dc.subjectcardiometabolic risk
dc.subjectcardiovascular mortality
dc.subjectcerebrovascular accident
dc.subjectcholesterol blood level
dc.subjectclinical practice
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectdiastolic blood pressure
dc.subjectfemale
dc.subjecthigh risk patient
dc.subjecthuman
dc.subjectincidence
dc.subjectischemic heart disease
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetabolic syndrome X
dc.subjectmortality
dc.subjectNetherlands
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectpredictive value
dc.subjectprevalence
dc.subjectprospective study
dc.subjectsystolic blood pressure
dc.subjecttriacylglycerol blood level
dc.subjectaged
dc.subjectCaucasian
dc.subjectcomplication
dc.subjectCoronary Disease
dc.subjectDiabetes Mellitus, Type 2
dc.subjectinsulin resistance
dc.subjectmetabolic syndrome X
dc.subjectmiddle aged
dc.subjectphysiology
dc.subjectrisk factor
dc.subjectUnited States
dc.subjectAged
dc.subjectCoronary Disease
dc.subjectDiabetes Mellitus, Type 2
dc.subjectEuropean Continental Ancestry Group
dc.subjectFemale
dc.subjectHumans
dc.subjectInsulin Resistance
dc.subjectMale
dc.subjectMetabolic Syndrome X
dc.subjectMiddle Aged
dc.subjectPrevalence
dc.subjectProspective Studies
dc.subjectRisk Factors
dc.subjectUnited States
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1186/s12933-016-0387-4
dc.description.sourcetitleCardiovascular Diabetology
dc.description.volume15
dc.description.issue1
dc.description.page69
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s12933-016-0387-4.pdf816.48 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons